



Advancing Accurate Risk Assessment & Clinical Management of Preeclampsia

Introducing the Lumella® GlyFN
rapid point-of care test





Early symptoms of preeclampsia are often ambiguous for accurate clinical stratification

- Clinical presentations involve uncertain indications of hypertension and proteinuria
- Less than 40% of women exhibit both hypertension and proteinuria before the development of overt preeclampsia
- Preeclampsia progression is unpredictable and often complicated by adverse outcomes




“Biochemical markers can improve accurate clinical stratification and expectant management”

Dr. Michael Gravett, Dept of Obgyn, University of Washington Medical Centre, Seattle, USA

Lumella® GlyFN Levels are elevated in preeclampsia*

In an observational cohort of 107 pregnant women, 45 normotensive and 62 diagnosed with preeclampsia, Lumella® GlyFN levels were elevated as early as the first trimester ($p < 0.001$).



*Rasanen et al. Maternal serum glycosylated fibronectin as a point-of care biomarker for assessment of preeclampsia. *American Journal of Obstetrics and Gynecology* 2015;212:82.e1-9

The Lumella® GlyFN point-of care test accurately estimates risk in women with suspected preeclampsia

In a prospective, observational study, in a cohort of 798 women suspected of preeclampsia, Lumella® GlyFN as a single biochemical marker showed the highest test performance for risk stratification of preeclampsia.

Biomarker performance characteristics for risk assessment of PE

	Sensitivity	Specificity
GlyFn (µg/ml)	0.985	0.928
PAPPA2 (ng/ml)	0.754	0.961
PIGF (pg/ml)	0.919	0.921
sFlt-1 (ng/ml)	0.97	0.437

"All of the biomarkers studied GlyFn, PAPPA2, PIGF, and sFlt-1 displayed good test performance for the diagnosis of PE (AUC of 0.99–0.86; Table 3), with GlyFn exhibiting the best overall performance."

Glycosylated fibronectin point-of-care test for diagnosis of preeclampsia in a low-resource setting: a prospective Southeast Asian population study - BJOG, 2020, 10.1111/1471-0528.16323

Key Benefits of Lumella® Point-of-Care test



Features

Benefits

Highest sensitivity (98.5%) amongst all bio markers



Enables triage rule in and rule out of Preeclampsia

5 µl of sample - no blood draw



Relatively painless for the patient

Finger stick whole blood test



No need for blood draw and centrifugation

Storage at Room Temperature



No time wasted in bringing the test cartridge to Room Temperature

Point-of-Care 10 minute results



Enables immediate hospitalization if necessary

No capital investment



Cost-effective

References:

1. Rasanen et al. Maternal serum glycosylated fibronectin as a point-of care biomarker for assessment of preeclampsia. *American Journal of Obstetrics and Gynecology* 2015;212:82.e1-9
2. BMC Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study - Huhn et al. *BMC Pregnancy and Childbirth* (2020) 20:128
3. BJOG Glycosylated fibronectin point-of-care test for diagnosis of preeclampsia in a low-resource setting: a prospective Southeast Asia population study- 2020.10.1111/1471-0528.16323

Contact us at info@diabetomics.com to order your Lumella® test system at a low introductory price



2345 NE Overlook Drive, #140, Hillsboro, OR 97006, USA.

Lumella® is a registered trademark of Diabetomics, Inc. © 2018 Diabetomics, Inc. | All Rights Reserved. LN-6155, Rev. A



Pending FDA approval
in the USA